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Commentary
DLB and PDD: the same or different? Is there a debate?
Debating is a formal method of interactive and
position-representational argument. It is a broader
form of argument than logical argument, since it
can include elements of persuasion in order to
appeal to the emotional responses of an audience.
For experienced debaters, any proposition can be
defended or destroyed and the outcome depends at
least as much on his or her persuasive powers as it
does on the facts of the matter.
The concept of DLB as a clinico-pathological
syndrome “separate” from AD emerged from a
series of debates held in Newcastle upon Tyne in
1995 during the first DLB Consortium meeting
(McKeith et al., 1996). The point at issue was
whether a subset of dementia patients had a
“variant” of AD or a different condition. Evidence
and persuasion were combined to achieve consensus
that many of these patients were sufficiently
different from AD clinically and pathologically to
warrant them being placed in a separate category
for which the term DLB was coined. In doing so
the Consortium satisfied the original meaning of
the Latin word “debatum,” which means to reach
an agreement.
The debate in which we are invited to engage by
Drs Revuelta, Aarsland and colleagues – namely, the
sameness or differentness of DLB and PDD – arose
as an unforeseen secondary consequence of these
events. By acknowledging a diagnostic category
of DLB, the Consortium members generated en
passant the need for a definition of PDD, since
it appeared to them that DLB and PDD could
not be said to be the same, a conclusion that
was based upon one observation and one opinion.
The observation was that up to 25% of autopsy-
confirmed dementia cases with LB pathology were
not significantly parkinsonian during life, suggesting
that they could not realistically be said to have PDD.
And the opinion was that DLB and PDD seemed to
be quite different clinical syndromes, at least in the
early stages, with the burden of impairments falling
on different parts of the nervous system in a different
temporal sequence. The need for this DLB/PDD
divide was stated in the form of the infamous
one-year rule which stated that if extrapyramidal
motor features had been present for 12 months or
more before the onset of dementia, the diagnosis
should be PDD but if dementia occurred within
12 months of the motor features, or indeed preceded
the motor features, the diagnosis should be DLB. It
was acknowledged at the time that this boundary in
time was entirely arbitrary and existed solely to draw
a line between two overlapping clinical syndromes.
A return to this boundary issue at the Third Meeting
of the International Dementia with Lewy Bodies
Consortium resulted in the following restatement
of this basic position:
The distinction between dementia with Lewy bodies
and Parkinson’s disease dementia as two distinct
clinical phenotypes, based solely on the temporal
sequence of appearance of symptoms has been
criticized by those who regard the different clinical
presentations as simply representing different points
on a common spectrum of Lewy body disease,
itself underpinned by abnormalities in alpha-synuclein
metabolism. This unitary approach to classification
may be preferable for molecular and genetic studies
and for developing therapeutics. Descriptive labels
that include consideration of the temporal course
are preferred for clinical, operational definitions.
Dementia with Lewy bodies should be diagnosed
when dementia occurs before or concurrently with
parkinsonism, while Parkinson’s disease with dementia
should be used to describe dementia that occurs in
the context of well-established Parkinson’s disease.
The appropriate term will depend on the clinical
situation and generic terms such as Lewy body
disease are often helpful. In research studies in which
distinction is made between dementia with Lewy
bodies and Parkinson’s disease with dementia, the
one-year rule between the onset of dementia and
Parkinsonism should be used. Adoption of other
time periods will simply confound data pooling or
comparison between studies. In other research settings
including pathologic studies and clinical trials, both
clinical phenotypes may be considered collectively
under categories such as Lewy body disease or alpha–
synucleinopathy. (McKeith et al., 2005)
Is it possible to resolve the DLB/PDD con-
undrum by further debate? Not even the
most articulate, persuasive and well-informed
protagonist could persuade me that the clinical
presentation of a patient with a ten-year history of
PD proceeding to dementia is the same as that of
the patient with probable DLB who presents with
fluctuating confusion and hallucinations. But these
probably represent the extremes of the spectrum
and the debate should be focused on how one
might classify the patient who presents with (say)
the insidious onset of mild Parkinsonism and
forgetfulness, or with visual hallucinations early
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in the course of PD. Neither PDD nor DLB
seems particularly appropriate for either of these
rather different clinical situations, although both
patients are probably destined to reach a similar
end stage of dementia and Parkinsonism if they
live long enough. Which suggests (although does
not prove) that both patients have the same “thing”
wrong with them, i.e. disease state, and are simply
manifesting it differently in the early stages. So
what should we call this disease state? It would
be unhelpful to generate more clinical diagnostic
labels to cover all the possible combinations and
variations in presentation that can and do occur
associated with Lewy body disease, especially if we
include dysautonomia and sleep disorders which
dominate the picture in some patients. If we did
so, we would end up with a dozen or more different
clinical epithets.
Which is why the Third DLB statement is
worded as it is. DLB and PDD describe two
clinical presentations that are sufficiently different
clinically to warrant different labels and which, as
Revuelta and Lippa suggest, are probably better
dealt with by a cognitive disorder or movement
disorder specialist respectively. For patients who
don’t fall into one of these categories, use of the term
Lewy body disease, accompanied by a description
of the presenting symptoms, may be much more
appropriate. e.g. “Mrs. H has a four-year history of
Lewy body disease, presenting first with postural-
instability, gait-difficulty Parkinsonism and with the
later development of orthostatic hypotension, visual
hallucinations and moderate dementia.”
The more subtle point, to which Aarsland et al.
apply most of their persuasive energy, is the extent
to which we can be sure that these different
clinical syndromes are truly representations of
the same underlying disease. Revuelta and Lippa
cannot really produce any convincing evidence that
there are any major pathological, neurochemical
or imaging parameters that vary substantially
between DLB and PDD, and their analogy of
cerebrovascular disease being a common process,
responsible for a multitude of different clinical
presentations, implies that they conclude much
the same about Lewy body disease, effectively,
agreeing with Aarsland et al. They go on to
elaborate that “cortical LBs and LNs are the
principal pathologic entity responsible for the
clinical dementia syndrome in both PDD and DLB
and correlate well with severity of dementia in both
entities.” Although in a gross anatomical way this
argument may stand up, with brainstem LB disease
approximating to motor PD and cortical LB disease
being associated with dementia, the story is clearly
more complicated than this. The current model
which views LB and LN as the key pathogenic
lesions of LB disease has been challenged by a recent
report that the majority of aggregated α-synuclein is
located neither as LB nor as LN but as much smaller
molecular weight moieties located in presynaptic
terminals (Kramer and Schulz-Schaeffer 2007).
These authors further suggest that these aggregates
may be synapto-toxic, causing an almost complete
loss of dendritic spines in the post-synaptic area.
One can see an analogy with recent debate about
which species of amyloid are toxic in AD, low
molecular weight oligomers being implicated in
inhibiting long-term potentiation, enhancing long-
term depression and reducing dendritic spine
density in the normal rodent hippocampus, through
activation of metabiotropic glutamate receptors and
N-methyl D-aspartate receptors (Selkoe, 2008).
Until we have a more complete understanding of the
corresponding patho-biology of α -synuclein related
neurodegenerative disorders, it may be premature
to engage in weighty debate as to whether DLB and
PD are the same or different in such regard.
The revised DLB diagnostic criteria also
propose that the additional presence of Alzheimer
type pathology colors the clinical presentation
very considerably. Two recently published papers
support this notion. Weisman et al. (2007) found
only one third of a series of 95 autopsy-confirmed
LB pathology dementia cases to have the probable
DLB syndrome, these cases generally having only
limited Alzheimer pathology. By contrast, Fujishiro
et al. (2008) found 90% of diffuse cortical LB cases
with Braak neurofibrillary tangles up to stage 5,
to have probable DLB clinically, compared with
only 20% with Braak Stage 6. Taken together, the
evidence suggests that what we as clinicians call
DLB is itself a rather heterogeneous and variable
“entity” and we would do well to bear that in mind.
So does any of this debate matter? Are PDD
and DLB not simply two contrived syndromes that
have some limited clinical usefulness but which
are of little other consequence? The answer to
this depends upon what we see as the value of
what we can do for our patients and their families.
Clinicians have a duty to make diagnoses that
describe and explain as fully as possible what the
patient is reporting and to use that diagnosis to
make management decisions and offer a prognosis.
It matters profoundly that we understand the nature
of the diagnostic categories that we are using, and
that we appreciate how they relate to underlying
biological processes. DLB and PDD are the handles
by which we can hold and manipulate this complex
disease area and without them we would struggle,
even more than we do already, to communicate
either with our patients or with each other. But even
as we use the terms we have to be prepared to admit
to gaps in our understanding, and to tolerate the fact
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that the system is less than perfect. I am encouraged
that despite Revuelta and Lippa and Aarsland and
colleagues having been set up to debate a difference,
they in fact appear to be arguing in the same general
direction. I agree with them both.
IAN MCKEITH
Institute for Ageing and Health
Newcastle University, Wolfson Research Centre
Campus for Ageing and Vitality
Newcastle upon Tyne, NE4 5PL, U.K.
Email: i.g.mckeith@ncl.ac.uk
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